Grail, Inc. (NASDAQ:GRAL - Get Free Report) hit a new 52-week high during trading on Friday . The company traded as high as $23.44 and last traded at $23.05, with a volume of 117261 shares trading hands. The stock had previously closed at $22.41.
Analysts Set New Price Targets
A number of research analysts recently commented on GRAL shares. Morgan Stanley started coverage on Grail in a research note on Wednesday, November 27th. They issued an "equal weight" rating and a $16.00 target price for the company. Wolfe Research started coverage on Grail in a research note on Friday, November 15th. They set a "peer perform" rating for the company. Finally, Guggenheim started coverage on Grail in a research note on Thursday, October 17th. They set a "neutral" rating for the company.
Get Our Latest Stock Analysis on Grail
Grail Stock Down 3.5 %
The stock has a 50 day simple moving average of $15.06.
Insiders Place Their Bets
In related news, CEO Robert P. Ragusa sold 123,454 shares of the firm's stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $14.02, for a total value of $1,730,825.08. Following the transaction, the chief executive officer now owns 612,661 shares in the company, valued at $8,589,507.22. This trade represents a 16.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Chun R. Ding purchased 35,000 shares of the firm's stock in a transaction that occurred on Thursday, October 3rd. The stock was purchased at an average price of $12.71 per share, for a total transaction of $444,850.00. Following the acquisition, the insider now owns 3,558,655 shares of the company's stock, valued at $45,230,505.05. The trade was a 0.99 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 58,829 shares of company stock worth $757,298 over the last three months.
Grail Company Profile
(
Get Free Report)
GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
Further Reading
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
